Recent advances in treatment of youth with type 1 diabetes: Better care through technology

Diabetic Medicine

Volumn 18, Issue 11, 2001, Pages 864-870

  Tamborlane, W V ^a   Bonfig, W ^a   Boland, E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glucose sensing; Inhaled insulin; Insulin analogues; Type 1 diabetes mellitus

Indexed keywords

GLUCOSE; GLUCOSE OXIDASE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

CLINICAL TRIAL; DEVICE; DIABETES CONTROL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; JUVENILE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PUBERTY; REVIEW; SELF MONITORING; TECHNOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; THERAPEUTICS;

EID: 0035688266     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2001.00626.x     Document Type: Review

References (42)

1. The effects of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial
2. The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial
3. Prolonged effect of intensive therapy on the risk of advanced complications in the Epidemiology of Diabetes Intervention and Complications (EDIC) follow-up of the DCCT cohort
4. Continuous subcutaneous insulin infusion: An approach to achieving normoglycemia
5. Reduction to normal of plasma glucose in juvenile diabetics by subcutaneous administration of insulin with a portable infusion pump
6. Resource utilization and costs of care in the Diabetes Control and Complications Trial
7. Intensive blood glucose control of sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
8. c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial
9. Coping skills training for youth on intensive therapy has long lasting effects on metabolic control and quality of life
10. CSII: A 'new' way to achieve strict metabolic control, decrease severe hypoglycemia and enhance coping in adolescents with type I diabetes
11. Low risk of hypoglycemia despite metabolic control at DCCT level in a population of children and adolescents using intensified insulin treatment
12. Efficacy and tolerance of insulin lispro in young diabetic children treated with CSII
13. Impaired insulin action in puberty: A contributing factor to poor glycemic control in adolescents with diabetes
14. [Lys (B28),Pro (B29)]-human insulin. A rapidly absorbed analogue of human insulin
15. Insulin resistance of puberty: A defect restricted to peripheral glucose metabolism
16. Lispro or regular insulin for multiple injection therapy in adolescents: Differences in the insulin and glucose levels overnight
17. Suppressed epinephrine responses during sleep: A contributing factor to the risk of nocturnal hypoglycemia in insulin-dependent diabetes
18. Comparative study of insulin lispro and regular insulin in prepubertal children with type 1 diabetes
19. Effectiveness of post-prandial Humalog in toddlers with diabetes
20. Insulin lispro in CSII: Results of a double-blind crossover study
21. c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps
22. Comparison of human regular insulin and lispro insulin after interruption of CSII and in the treatment of acutely decompensated IDDM
23. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens
24. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, ultralente human insulin and continuous subcutaneous infusion of insulin lispro
25. Time-action profile of the long-acting analog glargine (HOE901) in comparison with those of NPH insulin and placebo
26. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
27. Efficacy and safety of HOE 901 versus NPH insulin in patients with type I diabetes
28. Insulin glargine (HOE901) lowers fasting glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycemia
29. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
30. Insulin glargine
31. Insulin administration intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects
32. Inhaled insulin
33. Time-action profile of inhaled insulin
34. Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomized proof of concept study
35. Inhaled human insulin treatment in patients with type 2 diabetes mellitus
36. Hypoglycaemia: Incidence and clinical predictors in a large population based sample of children and adolescents with IDDM
37. Limitations of conventional methods of self blood glucose monitoring: Lessons learned from three days of continuous glucose monitoring in pediatric patients with type I diabetes
38. Short-term use of the MiniMed continuous monitoring system to determine patterns of glycemia in pediatric patients with type I DM
39. Continuous glucose monitoring used to adjust diabetes therapy improved glycosylated hemoglobin: A pilot study
40. Performance evaluation of the MiniMed continuous monitoring system during patient home use
41. Counterregulation in peripheral tissues: Effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue
42. Clinical control of diabetes by the artificial pancreas